title: Three different brain tumours evolving from a common origin.
abstract: Despite an improved understanding of the molecular aberrations that occur in glioblastoma, the use of molecularly targeted therapies have so far been disappointing. We present a patient with three different brain tumours: astrocytoma, glioblastoma and gliosarcoma. Genetic analysis showed that the three different brain tumours were derived from a common origin but had each developed unique genetic aberrations. Included in these, the glioblastoma had PDGFRA amplification, whereas the gliosarcoma had MYC amplification. We propose that genetic heterogeneity contributes to treatment failure and requires comprehensive assessment in the era of personalised medicine.
authors.affiliation: Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Blizard Institute, London, UK.
authors.forename: T
authors.initials: T
authors.lastname: Forshew
authors.forename: P
authors.initials: P
authors.lastname: Lewis
authors.forename: A
authors.initials: A
authors.lastname: Waldman
authors.forename: D
authors.initials: D
authors.lastname: Peterson
authors.forename: M
authors.initials: M
authors.lastname: Glaser
authors.forename: C
authors.initials: C
authors.lastname: Brock
authors.forename: D
authors.initials: D
authors.lastname: Sheer
authors.forename: P J
authors.initials: PJ
authors.lastname: Mulholland
references.citation: Cell Cycle. 2006 Apr;5(7):783-91
references.pmid: 16582634
references.citation: Cancer Cell. 2011 Dec 13;20(6):810-7
references.pmid: 22137795
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1168-74
references.pmid: 20124186
references.citation: N Engl J Med. 2001 Jan 11;344(2):114-23
references.pmid: 11150363
references.citation: Nature. 2010 Dec 9;468(7325):824-8
references.pmid: 21102434
references.citation: Cancer Res. 2005 Jul 15;65(14):6071-9
references.pmid: 16024607
references.citation: Neuro Oncol. 2007 Jul;9(3):291-7
references.pmid: 17504929
references.citation: J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2
references.pmid: 20159801
references.citation: Cancer Cell. 2010 Jan 19;17(1):98-110
references.pmid: 20129251
references.citation: Cancer Res. 2004 Oct 1;64(19):6892-9
references.pmid: 15466178
references.citation: Nat Genet. 2009 Aug;41(8):899-904
references.pmid: 19578367
references.citation: Neoplasia. 2009 May;11(5):448-58, 2 p following 458
references.pmid: 19412429
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: N Engl J Med. 2012 Mar 8;366(10):883-892
references.pmid: 22397650
references.citation: Science. 2008 Sep 26;321(5897):1807-12
references.pmid: 18772396
references.citation: Am J Hum Genet. 2007 Jul;81(1):114-26
references.pmid: 17564968
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6
references.pmid: 22323597
references.citation: J Neurooncol. 2010 Feb;96(3):313-20
references.pmid: 19618114
references.citation: Cancer Res. 2012 Apr 1;72(7):1614-20
references.pmid: 22311673
references.citation: Expert Opin Emerg Drugs. 2005 Nov;10(4):845-54
references.pmid: 16262566
references.citation: Am J Pathol. 2007 May;170(5):1445-53
references.pmid: 17456751
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Br J Cancer. 2008 Jun 3;98(11):1830-8
references.pmid: 18506188
references.citation: N Engl J Med. 2009 Feb 19;360(8):765-73
references.pmid: 19228619
references.citation: N Engl J Med. 2005 Nov 10;353(19):2012-24
references.pmid: 16282176
references.citation: Nature. 2009 Oct 8;461(7265):809-13
references.pmid: 19812674
references.citation: Neuro Oncol. 2009 Apr;11(2):183-91
references.pmid: 18780813
references.citation: Sci Transl Med. 2012 May 30;4(136):136ra68
references.pmid: 22649089
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Clin Cancer Res. 2010 Apr 15;16(8):2443-9
references.pmid: 20371685